olanzapine LAI (TEV-'749) / Royalty, Teva, MedinCell 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
olanzapine LAI (TEV-'749) / Teva, MedinCell
2022-001865-11: A Study to Test if TV-44749 is Effective in Relieving Schizophrenia

Not yet recruiting
3
640
Europe
Olanzapine, TV44749, Powder and solvent for prolonged-release suspension for injection
Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia is a serious mental disorder in which people interpret reality abnormally. It is a severely debilitating psychotic disorder characterized by positive symptoms (eg, delusions, hallucinations, and grossly disorganized behavior) and negative symptoms (eg, affective flattening, alogia, and avolition)., Schizophrenia is a mental disorder that may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning and can be disabling, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
SOLARIS, NCT05693935: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

Active, not recruiting
3
675
Europe, US, RoW
TV-44749 - Dose level 1, TV-44749 - Dose level 2, TV-44749 - Dose level 3, Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia
03/24
01/25
NCT06315283: An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

Recruiting
1
116
Europe, US, RoW
TV-44749, Olanzapine, Oral olanzapine, ZYPREXA®
Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia
04/25
04/25
NCT06253546: Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

Recruiting
1
36
RoW
TV-44749, Oral Olanzapine, ZYPREXA
Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia
01/25
01/25
NCT06319170: Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Recruiting
1
95
US
Olanzapine Extended Release, Olanzapine, ZYPREXA
Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia, Schizoaffective Disorder
12/24
12/24

Download Options